Patient Satisfaction After Switching to Jatenzo (Oral Testosterone Undecanoate): Update on an Open-label, Single-arm Clinical Trial

Eur Urol Focus. 2023 Jan;9(1):17-19. doi: 10.1016/j.euf.2022.08.005. Epub 2022 Sep 3.

Abstract

This is the first study investigating patient satisfaction among men receiving oral testosterone decanoate (TU) who were previously using other forms of testosterone therapy. Oral TU appeared to lead to greater patient satisfaction in comparison to previous modalities and similar improvements in hypogonadal symptoms. TU represents a favorable and viable option for hypogonadal individuals who are unhappy with existing treatment options.

Publication types

  • Clinical Trial

MeSH terms

  • Humans
  • Hypogonadism* / drug therapy
  • Injections, Intramuscular
  • Male
  • Patient Satisfaction
  • Testosterone / therapeutic use

Substances

  • testosterone undecanoate
  • Testosterone